Popular Articles
Stretch Mark

GTx-758, An Oral LH Inhibitor For First Line Treatment Of Advanced Prostate Cancer, Advances Into Second Phase I Clinical Trial
GTx, Inc. (Nasdaq: GTXI), announced the initiation of a Phase I multiple ascending dose clinical trial evaluating GTx-758, an oral LH inhibitor for first line treatment of advanced prostate cancer. A Phase I single ascending dose clinical trial in 96 subjects was successfully completed in June.
generic viagra online
Obama Leaves Door Open To Tax On Health Benefits
"President Barack Obama on Wednesday rejected the idea of fully taxing Americans" employer-provided health insurance benefits, but suggested he might be persuaded to tax so-called Cadillac coverage ... in the interest of a compromise with Congress," McClatchy/The Star-Telegram reports. The President, speaking at a "town hall-style event" taped at the White House and aired on ABC News, "said he would prefer to pay for expanded coverage by eliminating some deductions for higher-earning taxpayers but that "there"s going to have to be some compromise." The President "said he understands Americans" trepidation about changing the system: "They know that they"re living with the devil, but the devil they know they think may be better than the devil they don"t." He said any reform would be phased in, not happen overnight" (Talev and Lightman, 6/24).
News of the day
Breast Cancer Help, Inc. Attends National Breast Cancer Coalition Annual Advocacy Conference In Washington, D.C.
As part of its community outreach, Breast Cancer Help, Inc. attended the annual National Breast Cancer Coalition (NBCC) conference, which was held May 2-5 at Washington, D.C. Representatives of Breast Cancer Help, along with hundreds of other activists, met at the nation"s capital to meet with elected officials who are responsible for the majority of the funding for breast cancer research. The conference was held to challenge the newly elected leaders in Washington to create the changes necessary to ensure the much-needed funding for research and access to quality care.
Nutrition

Two New Studies On Circadian Rhythms

Dartmouth Medical School geneticists have made new inroads into understanding the regulatory circuitry of the biological clock that synchronizes the ebb and flow of daily activities, according to two studies published May 15. Research on the relationship between clocks and temperature, reported in Cell, offers insight into a longstanding puzzle of temperature compensation: why the 24-hour circadian rhythm does not change with temperature when metabolism is so affected. A related study, in Molecular Cell, tracks a clock protein in action, mapping hundreds of highly choreographed modifications and interactions to provide the first complete view of regulation across a day. The new work adds clarity to the molecular underpinnings of circadian clocks, the finely tuned cellular timekeepers that drive most organisms. Circadian systems are biological oscillators that orchestrate activities through an elaborate network of interactive proteins and feedback loops. All clocks rely on transfer of phosphate groups, called phosphorylation, to clock proteins for setting the 24-hour cycle. Both studies looked at phosphorylation of the frequency (FRQ) clock protein, a central feedback cog in the fungal clock system. They build on the research of team leaders, Drs. Jay Dunlap and Jennifer Loros, who have documented the workings of FRQ and most other components in the Neurospora clock. "The Cell paper describes how the cell uses phosphorylation of a clock protein to keep the period length of the cycle close to the same across a range of temperatures. This phenomenon, called temperature compensation, is one of the few canonical properties of rhythms that still lack molecular description," said Dunlap. "The one in Molecular Cell describes collaborative work with Dr. Scott Gerber in the Norris Cotton Cancer Center. We used mass spectrometry to follow the degree of phosphorylation of over 75 sites on the FRQ clock protein across the day. Most proteins have one or a few phosphorylations, so following these across time is a major technical achievement as well as being informative for the clock biology." In Cell, the researchers suggest a new role for the clock-associated enzyme, casein kinase (CK)2 as a key control for temperature compensation. Pursuing two uncharacterized circadian protein mutants shown to affect compensation in an unusual way, the investigators identified different subunits of the same enzyme, CK2. They developed new ways to manipulate the genome and showed, by controlling expression, that the level of CK2 dictates the form of compensation through the phosphorylation of the clock protein FRQ. The property is unique to CK2 and shared with none of the other similar enzymes implicated in clock function. Coauthors in addition to Dunlap, professor of genetics and Loros, professor of biochemistry and of genetics, are Arun Mehra, Mi Shi, Christopher L. Baker, Hildur V. Colot. The second study traced protein interactions throughout the cycles to demonstrate how phosphorylation controls circadian rhythm. Using a heavy isotope labeling method and quantitative mass spectrometry, the researchers pinpointed a near record number of modifications on FRQ and described how each appears and disappears over the day. Moreover, their methods facilitated the identification of interacting proteins to track and correlate changes in the core circadian network. They determined the clusters and locations of known sites, and through mutational analysis identified novel functional domains to create a dynamic view of a clock protein in action. Co-authors with Dunlap, Loros, and Gerber, an assistant professor of genetics, are Christopher L. Baker,1 and Arminja N. Kettenbach. The work was supported by National Institutes of Health grants from the National Institute of General Medical General Medical Sciences. Sue Knapp Dartmouth College


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):